Study of bb21217 in Multiple Myeloma
Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
- ClinicalTrials.gov Identifier: NCT03274219
- Protocol Number: 17-379
- Principal Investigator: Jacalyn Rosenblatt
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required